Massachussetts Biotech Co. Faces Major Melanoma Drug Setback

1. Cori Fisher wrote this article for Streetwise Reports LLC and provides services to Streetwise Reports as an employee. 
2.  This article does not constitute investment advice and is not a solicitation for any investment. Streetwise Reports does not render general or specific investment advice and the information on Streetwise Reports should not be considered a recommendation to buy or sell any security. Each reader is encouraged to consult with his or her personal financial adviser and perform their own comprehensive investment research. By opening this page, each reader accepts and agrees to Streetwise Reports' terms of use and full legal disclaimer. Streetwise Reports does not endorse or recommend the business, products, services or securities of any company. 
3. This article does not constitute medical advice. Officers, employees and contributors to Streetwise Reports are not licensed medical professionals. Readers should always contact their healthcare professionals for medical advice.

For additional disclosures, please click here.

1. Ownership and Share Structure Information

The information listed above was updated on the date this article was published and was compiled from information from the company and various other data providers.

A Complete Response Letter (CRL) from the U.S. Food and Drug Administration (USDA) has been released for Replimune Group Inc.'s (REPL:NASDAQ) advanced melanoma cancer drug, RP1. In response to the company's Biologics License Application (BLA), the FDA decided to deny the application, with a senior case member formerly on the project stating that the ". . .  BLA clinical team thought the applicant had provided adequate evidence to support contribution of effect of RP1 plus nivolumab, but leadership did not agree." The company offered to meet with the BLA team throughout the review process, but the team declined.

The BLA team was 'new' and comprised of members the company had not interacted with before.

Sushil Patel, Ph.D., and CEO of Replimune, said in response to the CRL, "It is deeply disappointing that the FDA has not exercised regulatory flexibility to meet patients’ needs given the data supporting strong efficacy and the favorable safety profile. Approximately 8,500 Americans with advanced melanoma die every year. The country's foremost melanoma specialists stood behind the RP1 data. Patients and caregivers pleaded for urgency. All of it was met with inconsistent communication and a fragmented and slow-moving regulatory process which clearly puts U.S. innovation at risk."

Patel continued, asserting the cost this delay could have for patients battling melanoma: "As we previously communicated, without timely accelerated approval, the development of RP1 will not be viable. We are devastated for our committed employees who have worked tirelessly for patients, but at this point, we have no choice but to eliminate jobs, including substantially scaling back our U.S.-based manufacturing operations. A treatment desperately needed by patients will not be available. Not because the medicine failed. Because the system did.”

The FDA argued that the presented data set was sufficient to allow the drug to be made available to patients, but Replimune disagreed. "In the IGNYTE trial, patients with confirmed progression on an anti-PD-1-based regimen who received RP1 plus nivolumab had a 34% response rate with a median duration of 24.8 months with a favorable safety profile."

Much progress has been made in previous BLA meetings, with the FDA permitting the company to submit a BLA based primarily on data from the Phase 2 IGNYTE trial, and even accepted the submission with a 'breakthrough therapy' designation. When Replimune received FDA feedback, a Phase 3 trial to satisfy regulatory requirements began to accelerate approval.

But according to an April 10, 2026, Stockwatch.com article, the blame for this denial may lie with the regulatory agency, not the company. The article asserts that several communication issues created contradictions, including:

"After testimony from melanoma experts, the agency did not raise further concerns about the heterogeneity of the patient population in IGNYTE and acknowledged that randomizing patients to an anti-PD1-only arm in the confirmatory study was not feasible.

Following an agency suggestion, the company submitted a proposal for a descriptive analysis from IGNYTE-3 supporting the contribution of components. The company also included data from IGNYTE showing median progression-free survival on RP1 plus nivolumab was 30.6 months compared to 4.4 months on their prior PD-1-based regimen. The company requested feedback; however, the FDA did not respond and subsequently accepted the resubmission as a complete response to the July 2025 CRL.

The FDA raised several points related to tumor assessment methodology. As requested by the FDA, responses in IGNYTE were assessed using RECIST 1.1 without modifications. In addition, the company provided detailed analyses showing no material difference in response rates between injected and non-injected lesions. The company also provided a comprehensive analysis, which showed that biopsies and surgical interventions did not impact tumor response."

RP1 (vusolimogene oderparepvec) is based on a proprietary strain of herpes simplex virus engineered with a fusogenic protein (GALV-GP R- and GM-CSF) to attack and kill tumors, and activate the anti-tumor immune response. Replimune is a pharma company focused on cancer treatment based out of Massachusetts, and its RPx platform is the company's primary focus.

Melanoma Market Demands Development

Worldwide, melanoma is the fifth most common form of cancer and was responsible for roughly 8,500 deaths in the U.S. in 2025. Replimune focuses on treating advanced melanoma, which is characterized by a cancerous spread from one tumor to other parts of the body.

In a February 26, 2026, article by Keith Speights for The Motley Fool, Speights said that the cost of treating cancer in the U.S. costs roughly US$200 billion in 2020, but that cost is expected to grow to US$245 billion by 2030. A rise in treatment costs also means a rise in stock prices, with Mordor Intelligence writing, "The Cancer Therapy Market size was valued at US$245.18 billion in 2025 and is estimated to grow from US$269.66 billion in 2026 to reach US$446.89 billion by 2031," effectively doubling the market.

Several Analysts Downgrade Stock

According to FactSet, on April 8, 2026, Cantor Fitzgerald analyst Li Watsek gave Replimune a Hold rating with no target price. On the same day, FactSet reported that Piper Sandler analyst Allison Bratzel also gave the company a Hold rating with a US$4 price target. FactSet noted that on April 10, 2026, the below ratings were made:

1. Leerink Partners analyst Jonathan Chang gave the company a Hold rating with a US$2 target price.
2. WedBush analyst Robert Driscoll gave the company a Hold rating with a US$2 target price. 
3. Jefferies analyst Roger Song shared a Buy rating with a US$2 target price. 
4. BMO Capital analyst Evan David Seigerman gave the company a sell rating with a US$1 target price.

On April 13, 2026, H.C. Wainwright & Co. analysts Robert Burns and Raghuram Selvaraju, Ph.D., downgraded Replimune's stock from a 'Buy' rating to a 'Sell' rating, removing their price target. They cited the ". . . FDA Complete Response Letter (CRL) for the company's lead asset RP-1 that has materially extended — and potentially eliminated — the drug's path to market."

In reference to the company's financial situation, Burns and Selvaraju wrote, " With no product revenue projected through at least fiscal year 2027, Replimune continues to operate as a pre-commercial entity. The company reported a net loss of US$247.3 million for fiscal year 2025 and is projected to widen its loss to approximately US$307.7 million in fiscal year 2026, before improving modestly to approximately US$250.3 million in fiscal year 2027. Research and development expenses are expected to remain the dominant cost driver, projected at approximately US$219.3 million in fiscal year 2026 and US$187.2 million in fiscal year 2027. On the balance sheet, Replimune held approximately US$269.1 million in cash against US$46.0 million in total debt as of the report date, providing some near-term runway but a limited cushion given the extended development timeline now anticipated."

Ownership & Share Structure¹

Replimune Group Inc. has a market cap of US$140.37 million, with 82.57 million shares outstanding. The company's 52-week range is US$1.50-US$13.24. The stock is wholly owned, with Institutions holding 97.32% of shares and Management & Insiders owning 2.68% of shares.